An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma

Michon, Jean; Hartmann, O.; Bouffet, Éric; Méresse, Valérie; Coze, Carole; Bordigoni, Pierre; Cattiaux, E; Ward, Nick; Bernard, Jean‐Louis; Lemerle, J; Zucker, J M; Philip, Thierry

doi:10.1016/s0959-8049(98)00061-6

Cited by 42 publications

(33 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Granulocyte colony stimulating factor (GCSF, CSF3) is often administered in hope of restoring neutrophil levels after myeloablative chemotherapy in these neuroblastoma patients [4]. GCSF is also employed to stimulate leukocytosis just before peripheral blood stem cell collection in high-risk neuroblastoma [5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Granulocyte colony stimulating factor alters the phenotype of neuroblastoma cells: implications for disease-free survival of high-risk patients

Gay

Chang

Rutland

et al. 2008

Journal of Pediatric Surgery

View full text Add to dashboard Cite

Corresponding Author: (Same for reprint requests), Oluyinka Olutoye, MB, ChB, PhD, Division of Pediatric Surgery, Baylor College of Medicine, 6621 Fannin St, CC650.00, Houston, TX 77030-2399, Tel: (832) Fax: (832) 825-3141, oolutoye@bcm.tmc.edu. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.Presented at the 39 th Annual Meeting of the Canadian Association of Pediatric Surgeons. Winner of the best basic science paper presentation (ANG). NIH Public Access NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author ManuscriptIntroduction-GCSF is commonly employed for the treatment of chemotherapy-induced neutropenia. Despite high-dose intensive chemotherapy for advanced stage neuroblastoma, the survival rate remains poor. GCSF therapy is quite common in these children, thus we questioned its effect on neuroblastoma cells. We hypothesized that exogenous GCSF stimulates the proliferation and invasive character of neuroblastoma cells.

show abstract

Section: Introductionmentioning

confidence: 99%

Granulocyte colony stimulating factor alters the phenotype of neuroblastoma cells: implications for disease-free survival of high-risk patients

Gay

Chang

Rutland

et al. 2008

Journal of Pediatric Surgery

View full text Add to dashboard Cite

show abstract

“…At the Birmingham Children's Hospital, 14 patients were enrolled from a potential 51 eligible during the study period. Of those not enrolled on the study, 8 declined due to the trauma associated with subcutaneous injections, 3 were unable to give informed consent, 21 were not approached to enter the study, and 5 declined for unspeci®ed reasons.…”

Section: Methodsmentioning

confidence: 99%

A randomised study of prophylactic G‐CSF following MRC UKALL XI intensification regimen in childhood ALL and T‐NHL

Little

Morland

Chisholm

et al. 2002

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

show abstract

“…Hematopoietic growth factors have been studied as adjunctive therapy to antimicrobial therapy for febrile neutropenic patients in several randomized, controlled trials [144][145][146][147][148][149][150][151][152][153][154][155]. These studies show that G-CSF (filgrastim) or granulocyte-macrophage colony-stimulating factor (sargramostim) used as part of the treatment of febrile neutropenic patients can consistently shorten the duration of neutropenia, but these agents have not consistently and significantly reduced other measures of febrile morbidity, including duration of fever, use of anti-infectives, or costs of management of the febrile neutropenic episode.…”

Section: Use Of Colony-stimulating Factors In Treatmentmentioning

confidence: 99%

2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients With Cancer

&NA;

2002

Infectious Diseases in Clinical Practice

View full text Add to dashboard Cite

An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma

Cited by 42 publications

References 19 publications

Granulocyte colony stimulating factor alters the phenotype of neuroblastoma cells: implications for disease-free survival of high-risk patients

Granulocyte colony stimulating factor alters the phenotype of neuroblastoma cells: implications for disease-free survival of high-risk patients

A randomised study of prophylactic G‐CSF following MRC UKALL XI intensification regimen in childhood ALL and T‐NHL

2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients With Cancer

Contact Info

Product

Resources

About